Apolipoprotein AI) Promotes Atherosclerosis Regression in Diabetic Mice by Suppressing Myelopoiesis and Plaque Inflammation.
Animals
Apolipoprotein A-I
/ genetics
Atherosclerosis
/ complications
Cholesterol
/ metabolism
Cholesterol, HDL
/ blood
Diabetes Mellitus, Experimental
/ chemically induced
Female
Hematopoietic Stem Cells
/ cytology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Leukocytosis
Lipoproteins, HDL
/ metabolism
Male
Mice
Mice, Inbred C57BL
Mice, Transgenic
Myeloid Cells
/ cytology
Myelopoiesis
Neutrophil Activation
Receptors, LDL
/ deficiency
apolipoproteins
arteriosclerosis
diabetes mellitus
leukocytosis
lipoproteins, HDL
macrophages
myelopoiesis
Journal
Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
entrez:
1
10
2019
pubmed:
1
10
2019
medline:
23
6
2020
Statut:
ppublish
Résumé
Despite robust cholesterol lowering, cardiovascular disease risk remains increased in patients with diabetes mellitus. Consistent with this, diabetes mellitus impairs atherosclerosis regression after cholesterol lowering in humans and mice. In mice, this is attributed in part to hyperglycemia-induced monocytosis, which increases monocyte entry into plaques despite cholesterol lowering. In addition, diabetes mellitus skews plaque macrophages toward an atherogenic inflammatory M1 phenotype instead of toward the atherosclerosis-resolving M2 state typical with cholesterol lowering. Functional high-density lipoprotein (HDL), typically low in patients with diabetes mellitus, reduces monocyte precursor proliferation in murine bone marrow and has anti-inflammatory effects on human and murine macrophages. Our study aimed to test whether raising functional HDL levels in diabetic mice prevents monocytosis, reduces the quantity and inflammation of plaque macrophages, and enhances atherosclerosis regression after cholesterol lowering. Aortic arches containing plaques developed in Diabetic wild-type mice had impaired atherosclerosis regression, which was normalized by raising HDL levels. This benefit was linked to suppressed hyperglycemia-driven myelopoiesis, monocytosis, and neutrophilia. Increased HDL improved cholesterol efflux from bone marrow progenitors, suppressing their proliferation and monocyte and neutrophil production capacity. In addition to reducing circulating monocytes available for recruitment into plaques, in the diabetic milieu, HDL suppressed the general recruitability of monocytes to inflammatory sites and promoted plaque macrophage polarization to the M2, atherosclerosis-resolving state. There was also a decrease in plaque neutrophil extracellular traps, which are atherogenic and increased by diabetes mellitus. Raising apolipoprotein AI and functional levels of HDL promotes multiple favorable changes in the production of monocytes and neutrophils and in the inflammatory environment of atherosclerotic plaques of diabetic mice after cholesterol lowering and may represent a novel approach to reduce cardiovascular disease risk in people with diabetes mellitus.
Sections du résumé
BACKGROUND
Despite robust cholesterol lowering, cardiovascular disease risk remains increased in patients with diabetes mellitus. Consistent with this, diabetes mellitus impairs atherosclerosis regression after cholesterol lowering in humans and mice. In mice, this is attributed in part to hyperglycemia-induced monocytosis, which increases monocyte entry into plaques despite cholesterol lowering. In addition, diabetes mellitus skews plaque macrophages toward an atherogenic inflammatory M1 phenotype instead of toward the atherosclerosis-resolving M2 state typical with cholesterol lowering. Functional high-density lipoprotein (HDL), typically low in patients with diabetes mellitus, reduces monocyte precursor proliferation in murine bone marrow and has anti-inflammatory effects on human and murine macrophages. Our study aimed to test whether raising functional HDL levels in diabetic mice prevents monocytosis, reduces the quantity and inflammation of plaque macrophages, and enhances atherosclerosis regression after cholesterol lowering.
METHODS
Aortic arches containing plaques developed in
RESULTS
Diabetic wild-type mice had impaired atherosclerosis regression, which was normalized by raising HDL levels. This benefit was linked to suppressed hyperglycemia-driven myelopoiesis, monocytosis, and neutrophilia. Increased HDL improved cholesterol efflux from bone marrow progenitors, suppressing their proliferation and monocyte and neutrophil production capacity. In addition to reducing circulating monocytes available for recruitment into plaques, in the diabetic milieu, HDL suppressed the general recruitability of monocytes to inflammatory sites and promoted plaque macrophage polarization to the M2, atherosclerosis-resolving state. There was also a decrease in plaque neutrophil extracellular traps, which are atherogenic and increased by diabetes mellitus.
CONCLUSIONS
Raising apolipoprotein AI and functional levels of HDL promotes multiple favorable changes in the production of monocytes and neutrophils and in the inflammatory environment of atherosclerotic plaques of diabetic mice after cholesterol lowering and may represent a novel approach to reduce cardiovascular disease risk in people with diabetes mellitus.
Identifiants
pubmed: 31567014
doi: 10.1161/CIRCULATIONAHA.119.039476
pmc: PMC6777860
mid: NIHMS1538374
doi:
Substances chimiques
Apolipoprotein A-I
0
Cholesterol, HDL
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Lipoproteins, HDL
0
Receptors, LDL
0
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1170-1184Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL114978
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL131481
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL045095
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL117226
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL129433
Pays : United States
Organisme : NIDDK NIH HHS
ID : DP3 DK108209
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL139909
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL092969
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK095684
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK017047
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL084312
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL144993
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Arch Intern Med. 2007 May 28;167(10):1068-74
pubmed: 17533210
Arch Intern Med. 2004 Jul 12;164(13):1422-6
pubmed: 15249351
Blood. 2014 May 1;123(18):2768-76
pubmed: 24366358
Circulation. 2014 Sep 23;130(13):1110-30
pubmed: 25114208
Eur J Clin Invest. 2010 Dec;40(12):1131-43
pubmed: 20695882
J Clin Lipidol. 2017 May - Jun;11(3):712-724.e5
pubmed: 28442299
Lancet. 1999 May 15;353(9165):1649-52
pubmed: 10335783
N Engl J Med. 2011 Jan 13;364(2):127-35
pubmed: 21226578
Atherosclerosis. 1978 Dec;31(4):465-71
pubmed: 215176
Circ Res. 2017 Feb 17;120(4):736-743
pubmed: 28209798
Am J Epidemiol. 2002 Jan 1;155(1):57-64
pubmed: 11772785
J Lipid Res. 2014 Feb;55(2):168-79
pubmed: 23812558
Am J Epidemiol. 2001 Oct 15;154(8):758-64
pubmed: 11590089
Diabetes Care. 2004 Feb;27(2):491-6
pubmed: 14747234
Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3781-6
pubmed: 16537455
Nat Rev Immunol. 2013 Oct;13(10):709-21
pubmed: 23995626
Arterioscler Thromb Vasc Biol. 2014 Apr;34(4):779-89
pubmed: 24407029
Circ J. 2010 Jun;74(6):1165-74
pubmed: 20467151
J Am Coll Cardiol. 2018 Jan 2;71(1):53-65
pubmed: 29301628
Biochem J. 2015 May 1;467(3):517-27
pubmed: 25742174
Endocrinol Metab Clin North Am. 1998 Sep;27(3):613-25, ix-x
pubmed: 9785056
Lancet. 2014 Aug 16;384(9943):618-625
pubmed: 25131981
Diabetes. 2011 Jun;60(6):1759-69
pubmed: 21562077
Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7166-71
pubmed: 21482781
Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1776-85
pubmed: 15976324
N Engl J Med. 1974 Jun 6;290(23):1275-8
pubmed: 4827627
N Engl J Med. 1998 Jul 23;339(4):229-34
pubmed: 9673301
Diabetologia. 2003 Jun;46(6):733-49
pubmed: 12774165
Am J Pathol. 2013 Dec;183(6):1981-1992
pubmed: 24113453
PLoS One. 2013 Aug 21;8(8):e74676
pubmed: 23991225
Nat Med. 2015 Jul;21(7):815-9
pubmed: 26076037
Cell Metab. 2013 May 7;17(5):695-708
pubmed: 23663738
J Clin Invest. 2017 Aug 1;127(8):2904-2915
pubmed: 28650342
Nat Rev Endocrinol. 2013 Dec;9(12):750-5
pubmed: 23835371
Circulation. 2018 Aug 28;138(9):898-912
pubmed: 29588315
Circ Res. 2014 Oct 10;115(9):759-69
pubmed: 25201910
Diabetes. 2015 Dec;64(12):4046-60
pubmed: 26253613
Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):434-8
pubmed: 1703299
J Clin Invest. 2007 Jan;117(1):185-94
pubmed: 17200718
Elife. 2016 Aug 30;5:
pubmed: 27572261
Diabetes. 2010 Jan;59(1):249-55
pubmed: 19833897
Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):2813-20
pubmed: 23152494
Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6731-5
pubmed: 1907375
Arterioscler Thromb Vasc Biol. 2004 Sep;24(9):1714-9
pubmed: 15256400
Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):843-9
pubmed: 19286630
J Lipid Res. 2007 Nov;48(11):2453-62
pubmed: 17761631
Clin Chem. 2014 Nov;60(11):1393-401
pubmed: 25225166
Science. 2010 Jun 25;328(5986):1689-93
pubmed: 20488992
Circulation. 2011 Mar 8;123(9):989-98
pubmed: 21339485
Lancet. 2010 Nov 13;376(9753):1670-81
pubmed: 21067804